- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01393223
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Michigan
-
Royal Oak, Michigan, Förenta staterna
- William Beaumont Hospitals
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
A patient is deemed suitable for inclusion in the study if the patient meets the following criteria:
- Male or female at least 18 years of age
IC/BPS diagnosed by a health care provider based the following criteria:
Complaint of suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and night time frequency, in the absence of proven urinary infection or other obvious pathology Have had IC/BPS symptoms for at least six months Score of ≥ 12 on the ICSI/PI at baseline Urinary frequency > 10 times a day by self-report and confirmed on baseline three-day voiding diary Have IC/BPS that in the judgment of the investigator has been stable in the previous 30 days IC/BPS-related pain defined as a score of > 3 cm and < 9 cm on the pain VAS where 0 is no pain and 10 is maximum pain
Have had inadequate clinical responses with conservative treatments, which may include one or more of the following: 1) timed voiding and behavioral modification therapy, 2) dietary restrictions, 3) stress reduction and/or 5) oral therapy with any of the following medications:
Antidepressants Antihistamines Antimuscarinic and anticholinergic agents Alpha adrenergic blockers Analgesics Pentosan polysulfate
- Women of childbearing potential: have a negative urine pregnancy test at screening, and must agree to use an acceptable from of contraception (oral contraceptives, intrauterine or double barrier methods), as agreed to by the investigator, during the study period
- Provide signed informed consent
- Subject agrees to be available for the follow-up evaluations as required by the protocol
Exclusion Criteria:
Patients are excluded from enrollment in the study if any of the following are true:
- Currently pregnant or breastfeeding, or plan to become pregnant during the course of the study
- Have received investigational products or devices within 30 days prior to screening visit
- Have received intravesical therapy or bladder hydrodistention within 30 days prior to screening visit. Intravesical instillations may include liquid or drug delivery devices, pentosan polysulfate sodium, lidocaine, steroid, heparin, chondroitin and any combination or additional formulation.
- Have participated in IC/BPS research trial within 90 days prior to screening visit or has not returned to baseline if participated in IC/BPS research trial greater than 90 days prior to screening visit
Have received any of the following medication within 30 days of screening visit, unless such medications have been administered at a stable dose during this month and are expected to remain at a stable dose throughout the study:
Antidepressants Antihistamines (use of antihistamines as needed for allergies is allowed) Anticonvulsants Antimuscarinic and anticholinergic agents Alpha adrenergic blockers Pentosan polysulfate sodium Oral chondroitin
- Have indicated use of > 70 mg of morphine equivalents of opioids per week to control their IC/BPS pain within 30 days prior to screening, or are expected to require this level of IC/BPS pain control during the study period
- Previous augmentation cystoplasty, cystectomy, neurectomy (i.e., hypogastric nerve plexus ablation). Bladder botulinum toxin injections within nine months prior to screening.
- Sacral and/or pudendal nerve neuromodulation device (Interstim) within the last 6 months. Subjects would not be excluded if they had Interstim greater than 6 months ago and is on a stable setting within the past 90 days
- Percutaneous Tibial Nerve Stimulation (PTNS) treatment within the past 90 days
- Evidence of renal impairment (creatinine > two times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > three times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment
- Post-void residual (PVR) urine volume of > 150 mL at screening
- Any condition that in the judgment of the investigator would interfere with the patient's ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which might confound the interpretation of the study results
- Previously received intravesical liposomes
- Urinary tract or prostatic infection in the past 90 days before study entry
- Active genital herpes or vaginitis
- Urethral diverticulum
- Pelvic malignancy within the past five years
- History of cyclophosphamide or chemical cystitis, or tuberculosis or pelvic radiation
- History of bladder or prostate tumors (benign or malignant)
- Uncontrolled diabetes
- Has any condition that would preclude treatment due to contraindications and/or warnings in the product labeling
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: LP-08 80mg
4 weekly intravesical administration of LP-08 80mg
|
Intravesical instillation of 80mg LP08
|
Aktiv komparator: LP-08 20mg
4 weekly intravesical administration of LP-08 20mg
|
Intravesical instillation of 20mg LP08
|
Placebo-jämförare: Normal Saline
Four weekly normal saline intravesical administration
|
Intravesical instillation of normal saline
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Safety of Intravesical LP08: number/severity of adverse events
Tidsram: Up to 31 weeks following treatment
|
The number/severity of adverse events throughout the study
|
Up to 31 weeks following treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Efficacy Voids Per Day (VPD)
Tidsram: 2, 4, 8, 16, 24 weeks following treatment
|
The change in voids per day (urinary frequency) as measured on a 3 day voiding diary
|
2, 4, 8, 16, 24 weeks following treatment
|
Efficacy Global Response Assessment (GRA)
Tidsram: 4, 8, 16, 24 weeks following treatment
|
Reporting a "moderate" or "marked" improvement on the GRA
|
4, 8, 16, 24 weeks following treatment
|
Efficacy Symptom
Tidsram: 2, 4, 8, 16, 24 weeks following treatment
|
The change in the symptoms and problems of interstitial cystitis from the baseline as measured by the O'Leary-Sant Interstitial Cystitis Symptom Index
|
2, 4, 8, 16, 24 weeks following treatment
|
Efficacy Visual Analog Scale (VAS)
Tidsram: 2, 4, 8, 16, 24 weeks following treatment
|
The change in pain as recorded on the VAS
|
2, 4, 8, 16, 24 weeks following treatment
|
Efficacy Diary
Tidsram: 2, 4, 8, 16, 24 weeks following treatment
|
The change from baseline in average voided volume, urgency and nocturia episodes per day as measured on a 3 day voiding diary
|
2, 4, 8, 16, 24 weeks following treatment
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PhaseII LP-08 IC/BPS
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Interstitiell cystit
-
Assiut UniversityHar inte rekryterat ännuNefrolitiasis, Glomerulonefrit, Amyloidos, AKI, CKD, Tubuli Interstitial | Urinvägsstörningar hos IBD-patienter
Kliniska prövningar på LP-08 80mg
-
Cartesian TherapeuticsRekryteringMyelom multipelFörenta staterna
-
3D Medicines (Beijing) Co., Ltd.Indragen
-
Guangzhou Magpie Pharmaceuticals Co., Ltd.Har inte rekryterat ännuPulmonell arteriell hypertoni
-
Breath of Life International Pharma LtdIndragen
-
Sun Pharma Advanced Research Company LimitedAvslutadBröstcancer och äggstockscancer
-
Nihon Pharmaceutical Co., LtdAvslutad
-
NobelpharmaAvslutad
-
Cartesian TherapeuticsRekryteringSystemisk lupus erythematosus (SLE)Förenta staterna
-
Cartesian TherapeuticsRekryteringMyasthenia Gravis, generaliseradFörenta staterna, Kanada
-
GenfitAvslutadTyp II diabetes mellitusBosnien och Hercegovina, Lettland, Makedonien, fd jugoslaviska republiken, Moldavien, Republiken, Rumänien, Serbien